Solventum (SOLV) Projected to Post Quarterly Earnings on Thursday

Solventum (NYSE:SOLV) is anticipated to announce its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of $1.50 per share and revenue of $1.9613 billion for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Solventum Trading Up 1.6%

NYSE:SOLV opened at $74.94 on Thursday. The stock’s 50 day moving average price is $79.61 and its 200 day moving average price is $76.15. Solventum has a 52 week low of $60.70 and a 52 week high of $88.20. The company has a market capitalization of $13.00 billion, a P/E ratio of 8.63, a P/E/G ratio of 6.77 and a beta of 0.35. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50.

Solventum declared that its Board of Directors has approved a share buyback plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 7.5% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.

Hedge Funds Weigh In On Solventum

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC bought a new position in Solventum in the third quarter valued at $25,000. CYBER HORNET ETFs LLC bought a new position in shares of Solventum during the 2nd quarter valued at about $28,000. MUFG Securities EMEA plc purchased a new position in shares of Solventum during the 2nd quarter valued at about $31,000. State of Wyoming bought a new stake in Solventum in the 2nd quarter worth approximately $33,000. Finally, Triumph Capital Management purchased a new stake in Solventum in the third quarter worth approximately $33,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SOLV shares. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Piper Sandler reissued an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. KeyCorp raised Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 price target for the company in a report on Monday, January 26th. BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Tuesday, December 2nd. Finally, Stifel Nicolaus raised their target price on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $90.83.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.